Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs

Indian Journal of Medical Research

Volumn 128, Issue 5, 2008, Pages 611-615

  Arya, D S ^a   Ojha, S K ^a   Semwal, O P ^a   Nandave, M ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Pharmacokinetics; Progressive primary disease of lungs; Pyrazinamide

Indexed keywords

PYRAZINAMIDE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BLOOD ANALYSIS; CHILD; DOSE RESPONSE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GROWTH INHIBITION; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCHOOL CHILD; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PYRAZINAMIDE; TUBERCULOSIS, PULMONARY;

EID: 61849106968     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Yepes JF, Sullivan J, Pinto A. Tuberculosis: medical 1. management update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 267-73.
2. Swaminathan S, Raghavan A, Duraipandian M, Kripasankar 2. AS, Ramachandran P. Short-course chemotherapy for paediatric respiratory tuberculosis: 5-year report. Int J Tuberc Lung Dis 2005; 9: 693-6.
3. Stowe CD, Jacobs RF. Treatment of tuberculus infection and 3. disease in children: the North American perspective. Paediatr Drugs 1999; 1: 299-312.
4. Albertini M. Treatment of tuberculosis in children. 4. Arch Pediatr 2005; 12: S110-S6.
5. Hu Y, Coates AR, Mitchison DA. Sterilizing action of pyrazinamide 5. in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2006; 10: 317-22.
6. Jacobs WR Jr. 6. Mycobacterium tuberculosis: a once genetically intractable organism. In: Hatfall GF, Jacobs WR Jr., editors. Molecular genetics of mycobacteria. Washington: ASM Press; 2000. p. 1-16.
7. Albisua IS, Vidal ML, Verde GJ, Castillo FD, Jose ID, Hortelano JG. Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. Pediatr Infect Dis J 1997; 16: 760-3.
8. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988; 94: 845-50.
9. Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis 1999; 3: 133-7.
10. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22: 686-95.
11. Correa AG. Unique aspects of tuberculosis in the paediatric population. Clin Chest Med 1997; 18: 89-98.
12. Peloquin C, Bulpitt A, Jaresko G, Jelliffe R, James G, Nix D. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with Antacids. Pharmacotherapy 1998; 18: 1205-11.
13. Peloquin C, Jaresko G, Yong C, Keung A, Bulpitt A, Jelliffe R. Population pharmacokinetic modeling of isoniazid, rifampin and pyrazinamide. Antimicrob Agents Chemother 1998; 41: 2670-9.
14. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231-49.
15. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50: 407-13.
16. Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 1999; 43: 1329-33.
17. Brouard A, Barreteau H, Merdjan H, Paillet M, Fredj G, Micoud M. Rapid determination of pyrazinamide in biological fluids by high-performance liquid chromatography. J Chromatogr 1985; 345: 453-6.
18. Stottmeier KD, Beam RE, Kubica GP. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis 1967; 96: 1072-5.
19. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-74.
20. Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G. Duwoos H. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989; 36: 395-400.
21. Acocella GA, Nonis G, Perna E, Patane G, Gialdroni G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Am Rev Respir Dis 1988; 138: 886-90.
22. Seth V, Beotra A, Semwal OP, Mukhopadhyaya S. Monitoring of serum rifampicin and isoniazid levels in childhood tuberculosis. Am Rev Respir Dis 1990; 141: A337.
23. Wallace RJ, Griffith DE Jr. Antimycobacterial agents. In: Kasper DI, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principle of internal medicine. 16th ed. New York: McGraw Hill; 2005. p. 946-53.
24. Saraf KA, Michielsen PP, Hauben EI, Lefebure A, Ramon AM, Van Marck EA. Hepatotoxicity after a short course of low-dose pyrazinamide. Acta Gastroenterol Belg 1996; 59: 251-3.
25. Geiter LJ, O'Brien RJ, Combs DL, Snider DE. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle 1987; 68: 41-6.
26. Reed MD, Blumer JL. Clinical pharmacology of antitubercular drugs. Pediatr Clin North Am 1983; 30: 177-93.
27. Carlone NA, Acocella G, Cuffini AM, Forno-Pizzoglio M. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am Rev Respir Dis 1985; 132: 1274-7.